Hydrogels are emerging as one of the most sought-after drug carriers due to their biocompatibility, high water content mimicking tissue-like environment, injectability, and stimuli responsiveness. Sustained drug release accompanied by targeted delivery to cancer cells can abate numerous adverse side effects of conventional chemotherapy. Folate receptors are overexpressed in various cancer cells, and their high binding affinity to folic acid (FA) makes folic acid-anchored drug carriers a specific targeting entity. Reports of folic acid-based hydrogels are still scarce, owing to their low solubility in water. In this study, we present a simple approach to generate a self-assembled supramolecular hydrogel by employing an amphiphilic low molecular weight gelator (LMWG), guanosine monophosphate (GMP), which noncovalently interacts and coassembles with FA. The hydrogel shows biocompatibility, thermoreversibility, self-healing, injectability, thixotropy, and self-adhesive properties. The hydrogel could encapsulate and release both hydrophilic (doxorubicin) and hydrophobic (curcumin) drugs in a sustained manner. studies on cancer cells showed that encapsulating the drugs within the hydrogel matrix resulted in enhanced uptake by the cancer cells, thereby increasing their therapeutic efficacy through upregulating tumor suppressor, apoptotic gene expression, and inhibiting cell proliferation markers. Thus, a straightforward fabrication procedure, cost-effectiveness, and treatment potency make the FA-GMP hydrogel a promising drug carrier for practical use in biomedical applications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acsami.4c21306 | DOI Listing |
Ann Med
December 2025
Department of Assisted Reproductive Centre, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, China.
Background: Butyrate may inhibit SARS-CoV-2 replication and affect the development of COVID-19. However, there have been no systematic comprehensive analyses of the role of butyrate metabolism-related genes (BMRGs) in COVID-19.
Methods: We performed differential expression analysis of BMRGs in the brain, liver and pancreas of COVID-19 patients and controls in GSE157852 and GSE151803.
J Cell Mol Med
March 2025
Hepatobiliary Center, the First Affiliated Hospital of Nanjing Medical University & Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.
The global incidence of biliary tract cancer (BTC) is on the rise, presenting a substantial healthcare challenge. The integration of immune checkpoint inhibitors (ICIs) with molecularly targeted therapies is emerging as a strategy to enhance immune responses. However, the efficacy and underlying mechanisms of these treatments in BTC are still largely unexplored.
View Article and Find Full Text PDFChemMedChem
March 2025
University of Windsor, Chemistry and Biochemistry, 401 Sunset Ave., N9B 3P4, Windsor, CANADA.
Boron Neutron Capture Therapy (BNCT) leverages the nuclear reaction between boron-10 and thermal neutrons to selectively destroy cancer cells while minimizing damage to surrounding healthy tissues. This therapy has found use in treating glioblastoma, which as a brain cancer, is difficult to treat using conventional radiotherapy, surgery, and chemotherapy due to location and the risk of brain damage. However, to work, the cells must contain 10B.
View Article and Find Full Text PDFACS Appl Bio Mater
March 2025
College of Chemistry and Chemical Engineering, Qingdao University, Qingdao 266071, China.
Photodynamic therapy (PDT) has been demonstrated to be an effective tool for cancer treatment. Seeking organelle-targeting photosensitizers (PSs) with robust reactive oxygen species (ROS) production is extremely in demand. Herein, we propose an aggregation-induced photosensitization strategy for effective PDT with osmium complexes.
View Article and Find Full Text PDFEur Urol
March 2025
Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address:
Owing to the "cold" tumor immune microenvironment of prostate cancer, immune-targeting agents have shown limited efficacy in patients with advanced prostate cancer, highlighting the need for new therapies with novel mechanisms of action. In this context, T-cell engagers (TCEs), which induce T-cell-mediated killing of cancer cells by binding the CD3 receptor on T cells and a specific tumor antigen expressed on malignant cells, represent a promising therapeutic option. Multiple studies have explored the use of TCEs in previously treated patients with metastatic castration-resistant prostate cancer, and several ongoing trials are currently assessing novel TCEs either as single agents or in combinatorial regimens with molecules with a distinct mechanism of action (eg, androgen receptor pathway inhibitors and other immune-targeting agents).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!